Adaptive Biotechnologies Corp
ADPT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001478320
In the last 90 days, Adaptive Biotechnologies Corp insiders filed 0 open-market purchases and 17 sales; 300 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; superinvestors Viking Global Investors and ARK Invest hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $51.0M in total
- 17
- 13F holdersQ2 2026, +6 vs. previous quarter
- 300
- 13F valueReported value at the end of Q2 2026
- $3.34B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding ADPT, Q2 2026
2 superinvestors report holding Adaptive Biotechnologies Corp on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.8%
Adaptive Biotechnologies Corp's share of the portfolio
- Shares
- 29,993,708
- Value
- $643.4M
ARK Invest
Cathie Wood
0.3%
Adaptive Biotechnologies Corp's share of the portfolio
- Shares
- 2,090,306
- Value
- $44.8M
Latest insider trades
Open-market purchases and sales by Adaptive Biotechnologies Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)8:17 PM ET | Sep 16 | 2 days | Lo FrancisChief People Officer | SSale | −115.4K | $28.06 | −$3.24M | −34.3%220.9K after | 2 lots10b5-1 |
| Sep 17, 2026 (view filing)6:50 PM ET | Sep 15 | 2 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −1.20K | $27.00 | −$32.3K | −0.3%395.8K after | 10b5-1 |
| Aug 28, 2026 (view filing)5:50 PM ET | Aug 26 | 2 days | Owen Katey EinterzDirector | SSale | −9.62K | $26.00 | −$250.0K | −10.9%78.6K after | |
| Aug 20, 2026 (view filing)5:55 PM ET | Aug 18 | 2 days | Hershberg RobertDirector | SSale | −30.7K | $24.40 | −$748.2K | −39.6%46.7K after | 2 lots |
| Aug 19, 2026 (view filing)8:15 PM ET | Aug 17-18 | 2 days | Robins Chad MCEO and Chairman | SSale | −600.0K | $24.80 | −$14.9M | −21.6%2.18M after | 4 lots |
| Aug 19, 2026 (view filing)8:07 PM ET | Aug 17 | 2 days | Neupert Peter MDirector | SSale | −124.7K | $25.15 | −$3.14M | −48.8%130.6K after | 3 lots |
| Aug 12, 2026 (view filing)7:33 PM ET | Aug 10 | 2 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −3.00K | $25.00 | −$75.0K | −0.8%397.0K after | 10b5-1 |
| Aug 3, 2026 (view filing)6:26 PM ET | Jul 30 | 4 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −1.30K | $24.00 | −$31.2K | −0.3%400.0K after | 10b5-1 |
| Jul 23, 2026 (view filing)7:34 PM ET | Jul 21 | 2 days | Robins Harlan SChief Scientific Officer | SSale | −492.4K | $21.89 | −$10.8M | −37.7%812.1K after | 2 lots10b5-1 |
| Jul 20, 2026 (view filing)7:19 PM ET | Jul 16 | 4 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −5.00K | $23.00 | −$115.0K | −1.2%401.3K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Adaptive Biotechnologies Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 29,993,708 | $643.4M | 1.83% | 00.0% | Unchanged |
| BlackRock, Inc. | 15,139,159 | $324.7M | 0.00% | +1,836,134+13.8% | Added |
| Vanguard Capital Management LLC | 6,403,587 | $137.4M | 0.00% | +309,443+5.1% | Added |
| Wellington Management Group LLP | 5,911,366 | $126.8M | 0.02% | +2,053,944+53.2% | Added |
| Vanguard Portfolio Management LLC | 5,476,231 | $117.5M | 0.01% | +984,757+21.9% | Added |
| D. E. Shaw & Co., Inc. | 4,625,859 | $99.2M | 0.06% | +2,660,249+135.3% | Added |
| Westfield Capital Management Co LP | 4,267,645 | $91.5M | 0.30% | −1,169,073−21.5% | Reduced |
| Geode Capital Management, LLC | 3,641,837 | $78.1M | 0.00% | +5,783+0.2% | Added |
| State Street Corp | 3,458,388 | $74.2M | 0.00% | +231,143+7.2% | Added |
| Invesco Ltd. | 3,094,011 | $66.4M | 0.01% | −1,356,055−30.5% | Reduced |